| Gout |
1 |
1 |
| Refractory |
0 |
0.9 |
| Adverse Effects |
0 |
0.23 |
| Washington DC |
0 |
0.16 |
| Clinical Guidelines |
0 |
0.15 |
| Clinical Research |
0 |
0.15 |
| Maryland |
0 |
0.15 |
| Patient Safety |
0 |
0.15 |
| Washington |
0 |
0.15 |
| Xanthines |
0 |
0.15 |
| Upper Respiratory Tract Infection |
0 |
0.11 |
| Healthcare and Medical Technology |
0 |
0.1 |
| Bone |
0 |
0.07 |
| Cellulitis |
0 |
0.07 |
| Europe |
0 |
0.07 |
| Hypertriglyceridemia |
0 |
0.07 |
| Intravenous |
0 |
0.07 |
| Otolaryngology |
0 |
0.07 |
| Pennsylvania |
0 |
0.07 |
| Respiratory Tract Infections |
0 |
0.07 |
| Stomatitis |
0 |
0.07 |